ABCL AbCellera Biologics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABCL

Price (delayed)

$6.53

Market cap

$1.99B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.48

Enterprise value

$2.03B

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 41

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners ...

Highlights
The company's quick ratio rose by 35% YoY and by 25% QoQ
AbCellera Biologics's net income has increased by 14% YoY
AbCellera Biologics's debt has soared by 112% YoY but it has decreased by 2.3% from the previous quarter
The equity has declined by 8% year-on-year and by 3% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.abcellera.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ABCL

ABCL stock price

How has the AbCellera Biologics stock price performed over time
Intraday
14.16%
1 week
13.96%
1 month
42.27%
1 year
169.83%
YTD
90.94%
QTD
87.11%

Financial performance

How have AbCellera Biologics's revenue and profit performed over time
Revenue
$79.21M
Gross profit
$79.21M
Operating income
-$211.96M
Net income
-$143.96M
Gross margin
100%
Net margin
-181.7%
AbCellera Biologics's operating margin has surged by 81% YoY and by 7% QoQ
AbCellera Biologics's net margin has soared by 75% YoY and by 7% from the previous quarter
ABCL's operating income is up by 34% year-on-year and by 2.4% since the previous quarter
AbCellera Biologics's net income has increased by 14% YoY

Price vs fundamentals

How does ABCL's price correlate with its fundamentals

Growth

What is AbCellera Biologics's growth rate over time

Valuation

What is AbCellera Biologics stock price valuation
P/E
N/A
P/B
2.11
P/S
24.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.58
ABCL's EPS is up by 14% YoY and by 2% from the previous quarter
ABCL's P/B is 54% above its last 4 quarters average of 1.2 but 8% below its 5-year quarterly average of 2.0
The equity has declined by 8% year-on-year and by 3% since the previous quarter
The P/S is 13% less than the last 4 quarters average of 25.2 but 9% more than the 5-year quarterly average of 20.0
The company's revenue rose by 5% QoQ

Efficiency

How efficient is AbCellera Biologics business performance
ABCL's ROS has soared by 76% YoY and by 5% from the previous quarter
The company's return on invested capital rose by 27% YoY and by 3.3% QoQ
The ROA has grown by 13% YoY
AbCellera Biologics's ROE has increased by 5% YoY

Dividends

What is ABCL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABCL.

Financial health

How did AbCellera Biologics financials performed over time
ABCL's current ratio is up by 38% YoY and by 24% QoQ
The company's quick ratio rose by 35% YoY and by 25% QoQ
AbCellera Biologics's debt is 86% less than its equity
The company's debt to equity has surged by 133% YoY
AbCellera Biologics's debt has soared by 112% YoY but it has decreased by 2.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.